Autoantibody explosion in antiphospholipid syndrome

Shoenfeld, Yehuda; Twig, Gilad; Katz, Uriel; Sherer, Yaniv

doi:10.1016/j.jaut.2007.11.011

Cited by 91 publications

(63 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many other antiphospholipid antibodies are described in APS, such as those reactive with phosphatidic acid and phosphatidylcholine, -ethanolamine, -glycerol, -inositol, and -serine (66 ). The measurement of antiannexin A5 antibodies has appeared useful in some situations (30,67 ).…”

Section: Apas Measured By Elisamentioning

confidence: 99%

“…The measurement of antiannexin A5 antibodies has appeared useful in some situations (30,67 ). Although a few studies report the association of antiphosphatidylethanolamine, antiprotein S antibodies, and antiannexin A2 antibodies with thrombosis and fetal loss, experience with such antibodies is limited (66,67 ). It is premature to include assays of other aPL antibodies in the daily work-up for APS because these assays have not been evaluated for precision and interlaboratory variation and standardization is lacking (68 ).…”

Section: Apas Measured By Elisamentioning

confidence: 99%

See 1 more Smart Citation

Challenges in the Diagnosis of the Antiphospholipid Syndrome

Devreese

Hoylaerts

2010

Clinical Chemistry

View full text Add to dashboard Cite

BACKGROUND:The antiphospholipid syndrome (APS) is an important cause of acquired thromboembolic complications and pregnancy morbidity. Its diagnosis is based on clinical and laboratory criteria, defined by strict guidelines. The original clinical and laboratory criteria for the identification of APS patients were published in 1999, in the so-called Sapporo criteria. In 2006 these criteria were revised, and recently more precise guidelines for analysis of the lupus anticoagulant have been provided. However, several questions related to the diagnosis of APS remain unanswered.CONTENT: In addition to providing a historical perspective, this review covers several challenges in the diagnosis of APS with respect to clinical and laboratory features, while highlighting pathogenic pathways of the syndrome. We discuss ongoing dilemmas in the diagnosis of this complex disease. Although antiphospholipid antibodies are found in association with various clinical manifestations, the older established clinical criteria were not substantively altered in the 2006 update. Several laboratory tests recommended in the latest criteria, including phospholipid-dependent coagulation tests for the detection of the lupus anticoagulant and ELISAs for measuring anticardiolipin and ␤2-glycoprotein I antibodies, still show methodological and diagnostic shortcomings. In addition, antiphospholipid antibodies have been described against other antigens, but their clinical role remains uncertain.

show abstract

Section: Apas Measured By Elisamentioning

confidence: 99%

Section: Apas Measured By Elisamentioning

confidence: 99%

Challenges in the Diagnosis of the Antiphospholipid Syndrome

Devreese

Hoylaerts

2010

Clinical Chemistry

View full text Add to dashboard Cite

show abstract

“…This activation has been demonstrated by the presence of at least 30 different types of autoantibodies related to APS. 27 The higher frequency of deep venous thrombosis in ANA Hep-2 positive individuals had been demonstrated in patients with SLE; 28,29 however, studies demonstrating these findings in patients with PAPS cannot be found in the literature. It is known that SLE patients are at higher risk to develop thromboembolic phenomena and that this risk is higher when antiphospholipid antibodies are present.…”

Section: Discussionmentioning

confidence: 98%

Avaliação clínico-laboratorial de pacientes com síndrome antifosfolípide primária segundo a frequência de anticorpos antinucleares (FAN Hep-2)

Carvalho¹,

Caleiro²,

Vendramini³

et al. 2010

Rev. Bras. Reumatol.

View full text Add to dashboard Cite

Objective: To evaluate the frequency of clinical and laboratory manifestations in patients with primary antiphospholipid syndrome (PAPS) with positive antinuclear antibodies (ANA Hep-2+) compared to those in whom this antibody is negative (ANA Hep-2-). Patients and Methods: This is a transversal study with 58 patients (82.8% females) with PAPS. Demographic and clinical data, comorbidities, medications, and antiphospholipid antibodies were evaluated. Results: Twenty (34.5%) out of 58 patients were positive for ANA Hep-2. Comparing the group of patients ANA Hep-2+ with those that were ANA Hep-2-, it was observed that both groups of patients with APS did not show statistically significant differences regarding demographic data, as well as the duration of the disease. As for clinical and laboratorial manifestations, the ANA Hep-2+ group showed higher frequency of deep venous thrombosis (85 versus 52.6%, P = 0.04), a statistically higher frequency of anticardiolipin IgG (85 versus 52.6%, P = 0.02), and a tendency for anticardiolipin IgM (80% versus 52.6%, P = 0.05), as well as greater medians of those antibodies [33 (0-128)

show abstract

“…PAPS is considered a systemic autoimmune disease in which a number of different autoantibodies have been described (34,35). Thrombosis seems to be the most important pathogenetic mechanism playing a role in organ involvement and tissue damage (36); however, not all of the clinical manifestations can be ascribed to thrombosis (36).…”

Section: Discussionmentioning

confidence: 99%